Long-acting version of Baxter's hemophilia drug succeeds in study

(Reuters) - Baxter International Inc said a more potent version of its flagship blood disorder drug Advate met the main goal in a late-stage study.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news